Sanofi - Aventis Groupe: Press Release: FDA accepts nirsevimab application as first protective option against RSV disease for all infants
FDA accepts nirsevimab application as first protective option against RSV disease for all infants Nirsevimab would be the first broadly protective option against RSV disease designed for all infants